MARLBOROUGH, Mass., Aug. 13, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 2024 Healthcare Conference on Wednesday, September 4, 2024.
Mike Mahoney, chairman and chief executive officer, and Dr. Brad Sutton, chief medical officer, Atrial Fibrillation Solutions, will participate in a 35-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET. A live webcast and replay of the session will be accessible at htts://investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.
CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
This email address is being protected from spambots. You need JavaScript enabled to view it.
Jon Monson
Investor Relations
+1 (508) 683-5450
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$96.98 |
Daily Change: | 4.99 5.42 |
Daily Volume: | 6,695,926 |
Market Cap: | US$142.560B |
January 08, 2025 November 25, 2024 November 15, 2024 November 04, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load